Biomarkers of cardiac disease

Expert Review of Molecular Diagnostics

Volumn 4, Issue 6, 2004, Pages 805-820

  Marian, A J ^a   Nambi, Vijay ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarkers; CK MB; CRP; HSP; Inflammation; Troponin

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADIPONECTIN; ASPARTATE AMINOTRANSFERASE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; CREATINE KINASE; CREATINE KINASE MB; DNA; FATTY ACID BINDING PROTEIN; GLYCOGEN PHOSPHORYLASE; HEART FATTY ACID BINDING PROTEIN; HEAT SHOCK PROTEIN; INTERLEUKIN 6; ISCHEMIA MODIFIED ALBUMIN; LACTATE DEHYDROGENASE; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; MYOGLOBIN; NITRIC OXIDE; PHOSPHOLIPASE A2; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERSICAN;

AMINO ACID SEQUENCE; ANEURYSM; AORTA DISSECTION; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DNA SEQUENCE; GENE EXPRESSION; GENE MAPPING; GENETIC LINKAGE; HAPLOTYPE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HUMAN; INFLAMMATION; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; PROGNOSIS;

EID: 8444228846     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.4.6.805     Document Type: Review

References (156)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nature Med. 4, 1241-1243 (1998).
2. Kannel WB, Dawber TR, Kagan A et al. Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study. Ann. Intern. Med. 55, 33-50 (1961).
3. Dawber TR, Kannel WB. An epidemiologic study of heart disease: the Framingham study. Nutr. Rev. 16, 1-4 (1958).
4. Manolio T. Novel risk markers and clinical practice. N. Engl. J. Med. 349, 1587-1589 (2003). Suggests criteria to assess the clinical utility of novel biomarkers.
5. Karmen A, Wroblewski F, Ladue JS. Transaminase activity in human blood. J. Clin. Invest. 34, 126-131 (1955).
6. Ladue JS, Wroblewski F, Karmen A. Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction. Science 120, 497-499 (1954).
7. Vasudevan G, Mercer DW, Varat MA. Lactic dehydrogenase isoenzyme determination in the diagnosis of acute myocardial infarction. Circulation 57, 1055-1057 (1978).
8. Amador E, Dorfman LE, Wacker WE. Serum lactic dehydrogenase activity: an analytical assessment of current assays. Clin. Chem. 12, 391-399 (1963).
9. Wong R, Swallen TO. Cellulose acetate electrophoresis of creatine phosphokinase isoenzymes in the diagnosis of myocardial infarction. Am. J. Clin. Pathol. 64, 209-216 (1975).
10. Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Ann. Rev. Biochem. 54, 831-862 (1985).
11. Tsung JS, Tsung SS. Creatine kinase isoenzymes in extracts of various human skeletal muscles. Clin. Chem. 32, 1568-1570 (1986). Creatine kinase isoenzymes mapped to different anatomical sites based on biopsies.
12. Ingwall JS, Kramer MF, Fifer MA et al. The creatine kinase system in normal and diseased human myocardium. N. Engl. J. Med. 313, 1050-1054 (1985).
13. Collinson PO, Stubbs PJ, Kessler AC. Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice. Heart 89, 280-286 (2003).
14. Schioler V, Thode J, Kjoller E. Performance characteristics of creatine kinase-MB isoenzyme measured with an immunoenzymometric and an immunoinhibition assay in acute myocardial infarction with and without thrombolytic therapy. Eur. J. Clin. Chem. Clin. Biochem. 30, 357-361 (1992).
15. Wolf PL. Common causes of false-positive CK-MB test for acute myocardial infarction. Clin. Lab. Med. 6, 577-581 (1986).
16. Pierce GF, Jaffe AS. Increased creatine kinase MB in the absence of acute myocardial infarction. Clin. Chem. 32, 2044-2051 (1986).
17. Puleo PR, Perryman MB. Noninvasive detection of reperfusion in acute myocardial infarction based on plasma activity of creatine kinase MB subforms. J. Am. Coll. Cardiol. 17, 1047-1052 (1991).
18. Puleo PR, Meyer D, Wathen C et al. Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N. Engl. J. Med. 331, 561-566 (1994). Reports superior performance of creatinine kinase-MB subforms compared with other conventional biomarkers for myocardial infarction (MI).
19. Malasky BR, Alpen JS. Diagnosis of myocardial injury by biochemical markers: problems and promises. Cardiol. Rev. 10, 306-317 (2002).
20. Fromm R, Meyer D, Zimmerman J et al. A double-blind, multicentered study comparing the accuracy of diagnostic markers to predict short- and long-term clinical events and their utility in patients presenting with chest pain. Clin. Cardiol. 24, 516-520 (2001). Only study comparing all major cardiac biomarkers in the diagnosis of acute MI and prognosis.
21. 2+-saturated form. Nature 424, 35-41 (2003).
22. Gahlmann R, Kedes L. Cloning, structural analysis, and expression of the human fast twitch skeletal muscle troponin C gene. J. Biol. Chem. 265, 12520-12528 (1990).
23. Gahlmann R, Wade R, Gunning P et al. Differential expression of slow and fast skeletal muscle troponin C. Slow skeletal muscle troponin C is expressed in human fibroblasts. J. Mol. Biol. 201, 379-391 (1988).
24. Farah CS, Reinach FC. The troponin complex and regulation of muscle contraction. FASEB J. 9, 755-767 (1995). Reviews the molecular models of the nature of calcium-induced structural transition in troponin.
25. Samson F, de Jong PJ, Trask BJ et al. Assignment of the human slow skeletal troponin T gene to 19q13.4 using somatic cell hybrids and fluorescence in situ hybridization analysis. Genomics 13, 1374-1375 (1992).
26. Mao C, Baumgartner AP, Jha PK et al. Assignment of the human fast skeletal troponin T gene (TNNT3) to chromosome 11p15.5: evidence for the presence of 11pter in a monochromosome 9 somatic cell hybrid in NIGMS mapping panel 2. Genomics 31, 385-388 (1996).
27. Mesnard L, Logeart D, Taviaux S et al. Human cardiac troponin T: cloning and expression of new isoforms in the normal and failing heart. Circ. Res. 76, 687-692 (1995). Describes expression of multiple cardiac troponin T expression in the heart in humans with heart failure.
28. Anderson PA, Greig A, Mark TM et al. Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. Circ. Res. 76, 681-686 (1995). Describes expression of multiple cardiac troponin T expression in the heart in humans with heart failure.
29. Zhu L, Perez-Alvarado G, Wade R. Sequencing of a cDNA encoding the human fast-twitch skeletal muscle isoform of troponin I. Biochim. Biophys. Acta. 1217, 338-340 (1994).
30. Collinson PO, Stubbs PJ. Are troponins confusing? Heart 89, 1285-1287 (2003).
31. Katus HA, Looser S, Hallermayer K et al. Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin. Chem. 38, 386-393 (1992).
32. Muller-Bardorff M, Hallermayer K, Schroder A et al. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin. Chem. 43, 458-466 (1997).
33. Azzazy HM, Duh SH, Fitzgerald RL et al. Multisite study of a second generation whole blood rapid assay for cardiac troponin T. Ann. Clin. Biochem. 36, 438-446 (1999).
34. James S, Armstrong P, Califf R et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am. J. Med. 115, 178-184 (2003).
35. Lindahl B, Diderholm E, Lagerqvist B et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J. Am. Coll. Cardiol. 38, 979-986 (2001). Data in this study shows that elevation of troponin T levels in the blood is associated with significant coronary stenosis and thrombus formation and increased risk of reinfarction and death. Very high levels of troponin T in the blood is associated with persistent occlusion of the culprit vessel, reduced left ventricular function and high mortality.
36. Lehrke S, Steen H, Sievers HH et al. Cardiac troponin T for prediction of short- and long-term morbidity and mortality after elective open heart surgery. Clin. Chem. 50(9), 1560-1567 (2004).
37. Wayand D, Baum H, Schatzle G et al. Cardiac troponin T and I in end stage renal failure. Clin. Chem. 46, 1345-1350 (2000). In this study, in-patients with end stage renal disease sporadic or persistently elevated troponin I or T predicts cardiac complications.
38. Goicoechea M, Garca de V, Gomez-Campdera F et al. Clinical significance of cardiac troponin T levels in chronic kidney disease patients: predictive value for cardiovascular risk. Am. J. Kidney Dis. 43, 846-853 (2004).
39. Dierkes J, Domrose U, Westphal S et al. Cardiac troponin T predicts mortality in patients with end stage renal disease. Circulation 102, 1964-1969 (2000).
40. Aviles RJ, Askari AT, Lindahl B et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N. Engl. J. Med. 346, 2047-2052 (2002). Analysis of 7033 patients enrolled in the Global Use of Strategies to Open Occluded Arteries trial with respect to troponin T and creatinine clearance. Troponin T is predictive of short-term outcomes irrespective of creatinine clearance.
41. Krause EG, Rabitzsch G, Noll F et al. Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction. Mol. Cell. Biochem. 160-161, 289-295 (1996).
42. Meyer F, Heilmeyer LM Jr, Haschke RH et al. Control of phosphorylase activity in a muscle glycogen particle. I. Isolation and characterization of the protein-glycogen complex. J. Biol. Chem. 245, 6642-6648 (1970).
43. Newgard CB, Littman DR, Van Genderen C et al. Human brain glycogen phosphorylase. Cloning, sequence analysis, chromosomal mapping, tissue expression, and comparison with the human liver and muscle isozymes. J. Biol. Chem. 263, 3850-3857 (1988).
44. Rabitzsch G, Mair J, Lechleitner P et al. Isoenzyme BB of glycogen phosphorylase b and myocardial infarction. Lancet 341, 1032-1033 (1993).
45. Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin. Chim. Acta. 272, 79-86 (1998).
46. Glatz JF, van der Vusse GJ. Nomenclature of fatty acid-binding proteins. Mol. Cell. Biochem. 98, 231-235 (1990).
47. Alhadi HA, Fox KAA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 97, 187-198 (2004).
48. Veerkamp JH, Peeters RA, Maatman RG. Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim. Biophys. Acta. 1081, 1-24 (1991).
49. Fournier NC, Richard MA. Role of fatty acid-binding protein in cardiac fatty acid oxidation. Mol. Cell. Biochem. 98, 149-159 (1990).
50. Bass NM, Manning JA. Tissue expression of three structurally different fatty acid binding proteins from rat heart muscle, liver, and intestine. Biochem. Biophys. Res. Commun. 137, 929-935 (1986).
51. Glatz JF, Kleine AH, van Nieuwenhoven FA et al. Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans. Br. Heart J. 71, 135-140 (1994).
52. Kleine AH, Glatz JF, van Nieuwenhoven FA et al. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol. Cell. Biochem. 116, 155-162 (1992). Heart fatty acid-binding protein was released into the serum in substantial amounts within 3.5 h of onset of symptoms of acute MI in this study of 22 patients.
53. Bhagavan NV, Lai EM, Rios PA et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin. Chem. 49, 581-585 (2003). Cobalt albumin binding assay was studied in 167 patients as a diagnostic tool to detect myocardial ischemia. High levels were associated with MI.
54. Sinha MK, Roy D, Gaze DC et al. Role of ischemia modified albumin, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg. Med. J. 21, 29-34 (2004).
55. Sinha MK, Gaze DC, Tippins JR et al. Ischaemia modified albumin is a sensitive marker of myocardial ischaemia after percutaneous coronary intervention. Circulation 107, 2403-2405 (2003).
56. Little WC, Constantinescu M, Applegate RJ et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 78, 1157-1166 (1988). A total of 42 consecutive patients who had coronary angiograms before and up to 1 month after MI were studied. Angiographic severity of coronary stenosis failed to accurately predict timing or location of subsequent coronary occlusion.
57. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94, 2013-2020 (1996). Eloquent review of plaque rupture by a leading authority.
58. Lusis AJ. Atherosclerosis. Nature 407, 233-241 (2000). Review of the pathogenesis of atherosclerosis.
59. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999). Excellent review of the pathogenesis of atherosclerosis and the role of inflammation by one of the pioneers in the field.
60. Yeh ETH. CRP as a mediator of disease. Circulation 109, II-11 (2004). Comprehensive review of the role of C-reactive protein (CRP), an inflammatory marker, in the pathogenesis of atherosclerosis.
61. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 109, II2-10 (2004). Eloquent review of CRP by leading authorities.
62. Pasceri V, Willerson JT, Yeh ET. Direct pro-inflammatory effect of C-reactive protein on human endothelial cells. Circulation 102, 2165-2168 (2000).
63. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. 116(Suppl.6A), 9S-16S (2004).
64. Paul A, Ko KWS, Li L et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109, 647-655 (2004). Provides direct evidence for the role of CRP in the pathogenesis of atherosclerosis.
65. Koenig W, Sund M, Frohlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99, 237-242 (1999).
66. Ridker PM, Buring JE, Shih J et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98, 731-733 (1998).
67. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331, 417-424 (1994).
68. Morrow DA, Rifai N, Antman EM et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction. J. Am. Coll. Cardiol. 31, 1460-1465 (1998).
69. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000). Data shows that CRP provides cardiovascular risk information additive to lipid levels in apparently healthy postmenopausal women.
70. Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286, 64-70 (2001). Prospective study demonstrating the ability of pravastatin to lower CRP levels.
71. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98, 839-844 (1998). Nested case-control study from the Cholesterol and Recurrent Events trial that studied the effects of prerandomization CRP and serum amyloid-A values on the subsequent development of a nonfatal or fatal coronary event. Patients with the higher levels of the inflammatory markers and in the placebo arm had the highest event rate.
72. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344, 1959-1965 (2001). Hypothesis that statins might prevent coronary events in patients with elevated CRP but no over hyperlipidemia was tested in the Air Force/Texas Coronary Atherosclerosis Prevention Study.
73. Latchman DS. Heat shock proteins and cardiac protection. Cardiovasc. Res. 51, 637-646 (2001). Discusses the role of heat shock proteins (HSPs) and their expression.
74. Morimoto RI. Cells in stress: transcriptional activation of heat shock genes. Science 259, 1409-1410 (1993). Reviews the role of HSPs in atherosclerosis with a particular focus on mechanistic studies.
75. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22, 1547-1559 (2002).
76. Gupta M, Vavasis C, Frishman WH. Heat shock proteins in cardiovascular disease a new therapeutic target. Cardiol. Rev. 12, 26-30 (2004).
77. Currie RW, Karmazyn M, Kloc M et al. Heat-shock response is associated with enhanced postischemic ventricular recovery. Circ. Res. 63, 543-549 (1988).
78. Zhu J, Quyyumi AA, Rott D et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103, 1071-1075 (2001).
79. Snoeckx LH, Cornelussen RN, van Nieuwenhoven FA et al. Heat shock proteins and cardiovascular pathophysiology. Physiol. Rev. 81, 1461-1497 (2001).
80. Wysocki J, Karawajczyk B, Gorski J et al. Human heat shock protein 60 (409-424) fragment is recognized by serum antibodies of patients with acute coronary syndromes. Cardiovasc. Pathol. 11, 238-243 (2002).
81. Vigh L, Literati PN, Horvath I et al. Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nature Med. 3, 1150-1154 (1997). Demonstrates that bimoclomol, a coinducer of HSPs, has signifiant therapeutic implications in cardiovascular disease.
82. Nanasi PP, Jednakovits A. Multilateral in vivo and in vitro protective effects of the novel heat shock protein coinducer, bimoclomol: results of preclinical studies. Cardiovasc. Drug Rev. 19, 133-151 (2001).
83. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 170, 191-203 (2003). Excellent review of cell adhesion molecules that also includes a list of known polymorphisms in the related genes.
84. Ikeda H, Takajo Y, Ichiki K et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 92, 1693-1696 (1995).
85. Ghaisas MD, Shahi MD, Foley MD et al. Elevated levels of circulating soluble adhesion molecules in peripheral blood of patients with unstable angina. Am. J. Cardiol. 80, 617-619 (1997).
86. Parker C III, Vita JA, Freedman JE. Soluble adhesion molecules and unstable coronary artery disease. Atherosclerosis 156, 417-424 (2001).
87. Hwang SJ, Ballantyne CM, Sharrett AR et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96, 4219-4225 (1997).
88. Ridker PM, Hennekens CH, Roitman-Johnson B et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351, 88-92 (1998).
89. Haim M, Tanne D, Boyko V et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. J. Am. Coll. Cardiol. 39, 1133-1138 (2002).
90. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103, 491-495 (2001).
91. Blankenberg S, Rupprecht HJ, Bickel C et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104, 1336-1342 (2001).
92. de Lemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J. Am. Coll. Cardiol. 36, 423-426 (2000).
93. Malik I, Danesh J, Whincup P et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358, 971-976 (2001).
94. Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2, 275-281 (1998).
95. Boring L, Gosling J, Cleary M et al. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894-897 (1998). Mice with selective absence of CCR2 receptor, the receptor for monocyte chemoattractant protein-1, when crossed with apolipoprotein E null mice (ApoE-deficient mice develop severe atherosclerosis), appears to decrease lesion formation markedly without altering the lipoprotein or lipid levels.
96. Boisvert WA, Santiago R, Curtiss LK et al. A leukocyte homolog of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest. 101, 353-363 (1998).
97. Mach F, Schonbeck U, Sukhova GK et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394, 200-203 (1998). Treatment of hyperlipidemic mice that lacked low-density lipoprotein-cholesterol receptors with antibodies against mouse CD40L limited atherosclerosis by supporting the involvement of inflammatory pathways in atherosclerosis and a role for CD40L signaling during atherogenesis in mice.
98. Seino Y, Ikeda U, Ikeda M et al. Interleukin-6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 6, 87-91 (1994).
99. Bruemmer D, Riggers U, Holzmeister J et al. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions. Am. J. Cardiol. 87, 21-27 (2001).
100. Ridker PM, Rifai N, Stampfer MJ et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767-1772 (2000).
101. Ridker PM, Rifai N, Pfeffer M et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 101, 2149-2153 (2000).
102. Skoog T, Dichtl W, Boquist S et al. Plasma tumor necrosis factor-α and early carotid atherosclerosis in healthy middle-aged men. Eur. Heart J. 23, 376-383 (2002).
103. Schonbeck U, Varo N, Libby P et al. Soluble CD40L and cardiovascular risk in women. Circulation 104, 2266-2268 (2001).
104. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343, 1148-1155 (2000).
105. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109, 837-842 (2004).
106. 2 levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol. 38, 1302-1306 (2001).
107. Zhang R, Brennan ML, Fu X et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286, 2136-2142 (2001). Demonstrates an association between coronary atherosclerosis and elevated levels of leukocyte and blood myeloperoxidase (MPO).
108. Baldus S, Heeschen C, Meinertz T et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108, 1440-1445 (2003).
109. Brennan ML, Penn MS, Van Lente F et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349, 1595-1604 (2003). Results show that plasma MPO levels were independent predictors of MI and the risk of major adverse cardiac events in 604 patients presenting with acute coronary syndrome to the emergency departments.
110. Garcia-Moll X, Coccolo F, Cole D et al. Serum neopterin and complex stenosis morphology in patients with unstable angina. J. Am. Coll. Cardiol. 35, 956-962 (2000).
111. Garcia-Moll X, Cole D, Zouridakis E et al. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart 83, 346-350 (2000).
112. Smith DA, Zouridakis EG, Mariani M et al. Neopterin levels in patients with coronary artery disease are independent of Chlamydia pneumoniae seropositivity. Am. Heart J. 146, 69-74 (2003).
113. Auer J, Berent R, Labetanig E et al. Serum neopterin and activity of coronary artery disease. Heart Dis. 3, 297-301 (2001).
114. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 90, 847-852 (2004).
115. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J et al. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am. J. Cardiol. 93, 627-629 (2004).
116. Gurfinkel EP, Scirica BM, Bozavidi G et al. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am. J. Cardiol. 83, 515-518 (1999).
117. Schumacher M, Eber B, Tatzber F et al. Neopterin levels in patients with coronary artery disease. Atherosclerosis 94, 87-88 (1992).
118. Walter RB, Fuchs D, Weiss G et al. HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease. Clin. Chem. Lab. Med. 41, 1314-1319 (2003).
119. Stulc T, Malbohan I, Malik J et al. Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastarin treatment. Am. Heart J. 146, E21 (2003).
120. Beaudeux JL, Burc L, Imbert-Bismut F et al. Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler. Tbromb. Vasc. Biol. 23, E7-E10 (2003).
121. Bayes-Genis A, Conover CA, Overgaard MT et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N. Engl. J. Med. 345, 1022-1029 (2001).
122. Cosin-Sales J, Christiansen M, Kaminski P et al. Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (pro-MBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 109, 1724-1728 (2004).
123. Lund J, Qin QP, Ilva T et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 108, 1924-1926 (2003).
124. Overgaard MT, Glerup S, Boldt HB et al. Inhibition of proteolysis by the proform of eosinophil major basic protein (proMBP) requires covalent binding to its target proteinase. FEBS Lett. 560, 147-152 (2004).
125. Johnatty SE, Dyck JR, Michael LH et al. Identification of genes regulated during mechanical load-induced cardiac hypertrophy. J. Mol. Cell. Cardiol. 32, 805-815 (2000).
126. Hwang JJ, Allen PD, Tseng GC et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end stage heart failure. Physiol. Genomics 10, 31-44 (2002). Demonstrates that a large number of genes are differentially expressed in cardiomypathies.
127. Hengstenberg C, Maisch B. Increased nuclear proto-oncogene expression in hypertrophic cardiomyopathy. Cardioscience 4, 15-20 (1993).
128. Kai H, Muraishi A, Sugiu Y et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ. Res. 83, 594-601 (1998).
129. Li RK, Li G, Mickle DA et al. Overexpression of transforming growth factor-β and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 96, 874-881 (1997).
130. Lim DS, Roberts R, Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J. Am. Coll. Cardiol. 38, 1175-1180 (2001).
131. Yang J, Moravec CS, Sussman MA et al. Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation 102, 3046-3052 (2000).
132. Sabbah HN, Sharov VG, Gupta RC et al. Reversal of chronic molecular and cellular abnormalities due to heart failure bypassive mechanical ventricular containment. Circ. Res. 93, 1095-1101 (2003).
133. Matsui H, MacLennan DH, Alpert NR et al. Sarcoplasmic reticulum gene expression in pressure overload-induced cardiac hypertrophy in rabbit. Am. J. Physiol. 268, C252-C258 (1995).
134. Lompre AM, Schwartz K, d'Albis A et al. Myosin isoenzyme redistribution in chronic heart overload. Nature 282, 105-107 (1979).
135. Mercadier JJ, Lompre AM, Wisnewsky C et al. Myosin isoenzyme changes in several models of rat cardiac hypertrophy. Circ. Res. 49, 525-532 (1981).
136. Miyata S, Minobe W, Bristow MR et al. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ. Res. 86, 386-390 (2000).
137. Holubarsch C, Goulette RP, Litten RZ et al. The economy of isometric force development, myosin isoenzyme pattern and myofibrillar ATPase activity in normal and hypothyroid rat myocardium. Circ. Res. 56, 78-86 (1985).
138. Ikeda U, Maeda Y, Yamamoto K et al. C-reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovasc. Res. 56, 86-92 (2002).
139. Yin WH, Chen JW, Jen HL et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am. Heart J. 147, 931-938 (2004).
140. Vasan RS, Sullivan LM, Roubenoff R et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107, 1486-1491 (2003).
141. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M et al. C-reacrive protein as a predictor of improvement and readmission in heart failure. Eur. J. Heart Fail. 4, 331-336 (2002).
142. Abassi Z, Karram T, Ellaham S et al. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Phamacol. Ther. 102, 223-241 (2004). Excellent review of natriuretic peptides that predominantly covers the clinical aspects of natriuretic peptides as biomarkers.
143. Ahluwalia A, MacAllister RJ, Hobbs AJ. Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res. Cardiol. 99, 83-89 (2004).
144. Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90, 195-203 (1994).
145. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 86, 1081-1088 (1992).
146. Richards AM, Nicholls MG, Yandle TG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97, 1921-1929 (1998).
147. Luchner A, Hengstenberg C, Lowel H et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 39, 99-104 (2002).
148. Harrison A, Morrison LK, Krishnaswamy P et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann. Emerg. Med. 39, 131-138 (2002).
149. Berger R, Huelsman M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105, 2392-2397 (2002).
150. De Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Eng. J. Med. 345, 1014-1021 (2001).
151. Richards AM, Nicholls MG, Espiner EA et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107, 2786-2792 (2003).
152. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med. 350, 647-654 (2004). Demonstrates that plasma levels of B-type natriuretic peptide in conjunction with other clinical information could be used to evaluate and treatment of patients with acute dyspnea who present to the emergency department.
153. Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130 (2000).
154. Bozkurt B, Mann DL. Use of biomarkers in the management of heart failure: are we there yet? Circulation 107, 1231-1233 (2003).
155. Sabatine MS, Morrow DA, De Lemos JA et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105, 1760-1763 (2002).
156. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur. Heart J. 25, 1187-1196 (2004).